Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amira Pharmaceuticals, Inc.

http://www.amirapharm.com/index.htm

Latest From Amira Pharmaceuticals, Inc.

A Year Of Paxlovid - Where Is The Licensed Generic?

A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.

Coronavirus COVID-19 Generic Drugs

A Year Of Paxlovid - Where Is The Licensed Generic?

It’s been a year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir. Scrip looks at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023 as Hetero's version becomes the first with WHO Prequalification while two Chinese and a Korean company wait in the wings.

Commercial Coronavirus COVID-19

Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Financing Innovation

'COVID Zero' Weakening Immune Systems? Flu Outbreaks Hit China

China reports flu outbreaks as COVID-19 cases decline, suggesting that population immunity may have been affected by the country's strict "COVID Zero" policies. The cost and availability of flu vaccines in the country are other policy factors playing into the situation. 

China Supply Chain
See All

Company Information

UsernamePublicRestriction

Register